Transenterix Inc (NYSEAMERICAN:TRXC) CFO Joseph P. Slattery sold 529,609 shares of Transenterix stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $2.80, for a total value of $1,482,905.20. Following the completion of the transaction, the chief financial officer now owns 440,974 shares of the company’s stock, valued at approximately $1,234,727.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Transenterix Inc (NYSEAMERICAN TRXC) traded down $0.21 during midday trading on Monday, hitting $2.13. The stock had a trading volume of 3,990,945 shares, compared to its average volume of 3,250,439. Transenterix Inc has a twelve month low of $0.45 and a twelve month high of $5.00.
A number of equities research analysts have recently issued reports on TRXC shares. Zacks Investment Research lowered Transenterix from a “buy” rating to a “sell” rating in a research report on Tuesday, August 8th. Stifel Nicolaus reiterated a “buy” rating and issued a $4.00 price objective (up from $3.75) on shares of Transenterix in a report on Monday, October 30th. Finally, Ladenburg Thalmann Financial Services set a $5.00 price objective on Transenterix and gave the company a “buy” rating in a report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $2.61.
A hedge fund recently raised its stake in Transenterix stock. Ladenburg Thalmann Financial Services Inc. grew its position in shares of Transenterix Inc (NYSEAMERICAN:TRXC) by 87.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 79,150 shares of the medical instruments supplier’s stock after purchasing an additional 37,000 shares during the quarter. Ladenburg Thalmann Financial Services Inc. owned approximately 0.05% of Transenterix worth $113,000 as of its most recent filing with the SEC.
COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2017/12/04/transenterix-inc-trxc-cfo-sells-1482905-20-in-stock.html.
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.